Kayoko Kaneko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kayoko Kaneko has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Atsuko Murashima
Japan Drug Information Institute in Pregnancy, Integrated Center for Women’s Health, National Center for Child Health and Development , Tokyo
10 shared publicationsEiko Miyagawa
Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development , Tokyo
5 shared publications- Akitsu Higuchi
Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development , Tokyo
4 shared publications Chinatsu Takai
Japan Drug Information Institute in Pregnancy, Integrated Center for Women’s Health, National Center for Child Health and Development , Tokyo
4 shared publicationsHaruhiko Sago
Department of Obstetrics, Center of Maternal‐Fetal, Neonatal and Reproductive Medicine National Center for Child Health and Development Tokyo Japan
4 shared publications- Atsuko Murashima
Division of Maternal Medicine, National Center for Child Health and Development, Tokyo, Japan
3 shared publications
Latest Publications
- 5 November 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
Transitional Care for Juvenile-onset Rheumatic and Musculoskeletal Diseases in Japan: A Web-based Survey of JCR and PRAJ Councillors/Board Members
Objective: To describe transitional care for juvenile rheumatic and musculoskeletal disorders in Japan and identify barriers/facilitators to collaboration between departments and facilities. Methods: We conducted a cross-sectional web-based survey in Japan (19 February–26 April 2025) targeting councillors/board members of the Japan College of Rheumatology and the Paediatric Rheumatology Association of Japan. Fisher’s exact tests and odds ratios were used for comparing adult and paediatric rheumatology services, and five major cities and others. Sparse cells were examined using Firth’s penalised logistic regression. Results: Of 159 submitted questionnaires, 122 were valid. Over 70% managed transitioned patients in the past 3 years. Respondents perceived that transition-related activity had increased (34.9%), whereas barriers remained unchanged (68.6%). Among adult rheumatology declining transitioned patients, 83.3% reported ‘no referral received’. Awareness/ever utilised was 73.3%/24.4% for the Transition Support Guide and 45.3%/23.3% for MIRAI TALK, a patient-held transition communication/support tool for paediatric rheumatic diseases. Paediatrics showed higher awareness and ever utilisation of both tools than adult rheumatology. Preconception care awareness was high, with 68.9% implementation and with significantly less frequent male-targeted counselling in adult rheumatology. Awareness of transitional care support centres was limited (one-third) and lower in adult rheumatology. Conclusion: Among surveyed rheumatology specialists, transition-related activity was perceived to have increased, but referral gaps, low adult-side tool uptake, and limited consultation pathways persist.
- 5 November 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
Transitional Care for Juvenile-onset Rheumatic and Musculoskeletal Diseases in Japan: A Web-based Survey of JCR and PRAJ Councillors/Board Members
Objective: To describe transitional care for juvenile rheumatic and musculoskeletal disorders in Japan and identify barriers/facilitators to collaboration between departments and facilities. Methods: We conducted a cross-sectional web-based survey in Japan (19 February–26 April 2025) targeting councillors/board members of the Japan College of Rheumatology and the Paediatric Rheumatology Association of Japan. Fisher’s exact tests and odds ratios were used for comparing adult and paediatric rheumatology services, and five major cities and others. Sparse cells were examined using Firth’s penalised logistic regression. Results: Of 159 submitted questionnaires, 122 were valid. Over 70% managed transitioned patients in the past 3 years. Respondents perceived that transition-related activity had increased (34.9%), whereas barriers remained unchanged (68.6%). Among adult rheumatology declining transitioned patients, 83.3% reported ‘no referral received’. Awareness/ever utilised was 73.3%/24.4% for the Transition Support Guide and 45.3%/23.3% for MIRAI TALK, a patient-held transition communication/support tool for paediatric rheumatic diseases. Paediatrics showed higher awareness and ever utilisation of both tools than adult rheumatology. Preconception care awareness was high, with 68.9% implementation and with significantly less frequent male-targeted counselling in adult rheumatology. Awareness of transitional care support centres was limited (one-third) and lower in adult rheumatology. Conclusion: Among surveyed rheumatology specialists, transition-related activity was perceived to have increased, but referral gaps, low adult-side tool uptake, and limited consultation pathways persist.
- 1 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70751
The Asia Pacific League of Associations for Rheumatology ( APLAR ) Consensus Statements for the Management of Reproductive Issues in Autoimmune Rheumatic Diseases
Background: The management of reproductive health in individuals with autoimmune rheumatic diseases (AIRDs) has evolved into a primary clinical priority. Wide variations in clinical practice and drug availability in the Asia‐Pacific regions necessitate localized frameworks. These consensus statements, developed by the Asia Pacific League of Associations for Rheumatology (APLAR) Special Interest Group for Women's Health & Reproductive Issues in Rheumatic and Musculoskeletal Diseases, aim to bridge the gaps within the region, foster multidisciplinary collaboration, and address regional knowledge deficits. Methods: An expert panel comprising 16 members of the 13 APLAR member nation organizations formulated 23 research questions using the PICO framework. A systematic review of English‐language literature up to July 2025 was conducted across the MEDLINE, Scopus, Google Scholar, and Cochrane Library databases, supplemented by a manual search of journals from the APLAR regions. Evidence from the APLAR region was appraised using the GRADE system. A modified Delphi online voting process was employed to reach consensus, pre‐defined as ≥ 75% agreement. Results: The panel approved four overarching principles and 86 statements, organized into 16 broad categories. These statements cover all three phases of pregnancy in AIRDs, the safety of medications during pregnancy and lactation, contraception, assisted reproductive techniques, fertility preservation, and hormonal replacement therapy, covering both female and male aspects as relevant. Conclusion: In a field often lacking high‐quality data, these consensus statements from APLAR provide expert opinion‐based guidance to support clinical decision‐making. It is envisaged that it will assist in educational and training purposes and help shape future research priorities.
- 1 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70751
The Asia Pacific League of Associations for Rheumatology ( APLAR ) Consensus Statements for the Management of Reproductive Issues in Autoimmune Rheumatic Diseases
Background: The management of reproductive health in individuals with autoimmune rheumatic diseases (AIRDs) has evolved into a primary clinical priority. Wide variations in clinical practice and drug availability in the Asia‐Pacific regions necessitate localized frameworks. These consensus statements, developed by the Asia Pacific League of Associations for Rheumatology (APLAR) Special Interest Group for Women's Health & Reproductive Issues in Rheumatic and Musculoskeletal Diseases, aim to bridge the gaps within the region, foster multidisciplinary collaboration, and address regional knowledge deficits. Methods: An expert panel comprising 16 members of the 13 APLAR member nation organizations formulated 23 research questions using the PICO framework. A systematic review of English‐language literature up to July 2025 was conducted across the MEDLINE, Scopus, Google Scholar, and Cochrane Library databases, supplemented by a manual search of journals from the APLAR regions. Evidence from the APLAR region was appraised using the GRADE system. A modified Delphi online voting process was employed to reach consensus, pre‐defined as ≥ 75% agreement. Results: The panel approved four overarching principles and 86 statements, organized into 16 broad categories. These statements cover all three phases of pregnancy in AIRDs, the safety of medications during pregnancy and lactation, contraception, assisted reproductive techniques, fertility preservation, and hormonal replacement therapy, covering both female and male aspects as relevant. Conclusion: In a field often lacking high‐quality data, these consensus statements from APLAR provide expert opinion‐based guidance to support clinical decision‐making. It is envisaged that it will assist in educational and training purposes and help shape future research priorities.
- 23 March 2026
- Published by SAGE Publications in Journal of Human Lactation
- Vol. 42 (2) , 485-491
Transfer of Bromazepam to Cord Blood and Breast Milk: A Case Series of Bromazepam Serum Levels and Outcomes in Newborns and Breastfed Infants
Introduction: Treatment for mental disorders in pregnant and lactating mothers is beneficial for both mothers and children. The potential effects of drugs used for mental health care during pregnancy and lactation on the fetus, neonate, and infant have not been fully elucidated for all drugs. Main issue: Information on placental transfer, transfer into breast milk, and outcomes for newborns and infants born to mothers who used bromazepam during the perinatal period is limited. Management: Three cases in women aged 20 to 40 (one case of bromazepam monotherapy, one case of concomitant zolpidem therapy, and one case of concomitant sertraline therapy) used bromazepam during pregnancy and lactation, and maternal serum and breast milk concentrations of bromazepam were measured through non-interventional sampling. Bromazepam cord blood concentrations were evaluated in two cases and were similar to maternal serum concentrations. Bromazepam elimination from breast milk was similar to elimination from maternal blood. The relative infant dose calculated from breast milk concentrations obtained from lactating women taking 3–6 mg of bromazepam daily ranged from 1.1% to 3.9%. All infants (whose feeding amounts were unknown and who were primarily formula-fed) were healthy, and no issues were identified during their 1-month and 3-month checkups. In the case of zolpidem co-administration, there was an emergency visit after discharge due to reduced crying, but there were no clinical problems. Conclusion: Bromazepam transfers into the placenta and breast milk, with no serious outcomes in neonates and infants, but one infant had unexplained lethargy. Further cases are needed.
- 23 March 2026
- Published by SAGE Publications in Journal of Human Lactation
- Vol. 42 (2) , 485-491
Transfer of Bromazepam to Cord Blood and Breast Milk: A Case Series of Bromazepam Serum Levels and Outcomes in Newborns and Breastfed Infants
Introduction: Treatment for mental disorders in pregnant and lactating mothers is beneficial for both mothers and children. The potential effects of drugs used for mental health care during pregnancy and lactation on the fetus, neonate, and infant have not been fully elucidated for all drugs. Main issue: Information on placental transfer, transfer into breast milk, and outcomes for newborns and infants born to mothers who used bromazepam during the perinatal period is limited. Management: Three cases in women aged 20 to 40 (one case of bromazepam monotherapy, one case of concomitant zolpidem therapy, and one case of concomitant sertraline therapy) used bromazepam during pregnancy and lactation, and maternal serum and breast milk concentrations of bromazepam were measured through non-interventional sampling. Bromazepam cord blood concentrations were evaluated in two cases and were similar to maternal serum concentrations. Bromazepam elimination from breast milk was similar to elimination from maternal blood. The relative infant dose calculated from breast milk concentrations obtained from lactating women taking 3–6 mg of bromazepam daily ranged from 1.1% to 3.9%. All infants (whose feeding amounts were unknown and who were primarily formula-fed) were healthy, and no issues were identified during their 1-month and 3-month checkups. In the case of zolpidem co-administration, there was an emergency visit after discharge due to reduced crying, but there were no clinical problems. Conclusion: Bromazepam transfers into the placenta and breast milk, with no serious outcomes in neonates and infants, but one infant had unexplained lethargy. Further cases are needed.
- Open Access
- 13 March 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 760-767
Efficacy of low-dose aspirin in preventing hypertensive disorders of pregnancy in women with systemic lupus erythematosus: A single-center retrospective cohort study
Objectives: Low-dose aspirin (LDA) is widely recommended to prevent hypertensive disorders of pregnancy (HDP). However, the evidence of its effectiveness in pregnancies with systemic lupus erythematosus (SLE) remains limited. This study evaluated the efficacy of LDA in preventing HDP in women with SLE. Methods: We conducted a retrospective cohort study of 124 pregnancies with SLE managed at our hospital. Pregnancy outcomes were compared between women treated with LDA and those not treated, using propensity score and inverse probability weighting analyses to adjust for confounders. Results: LDA was used in 65 pregnancies and not used in 59. HDP occurred in 7/65 (10.8%) and 8/59 (13.6%), respectively. After adjusting for potential confounders, including antiphospholipid antibodies, lupus nephritis, chronic hypertension, chronic kidney disease, history of HDP, and hydroxychloroquine use, the risk ratio for HDP with LDA was 0.76 (95% confidence interval: 0.25–2.33; P = .64). Sensitivity analysis was consistent. Conclusions: LDA did not significantly reduce the incidence of HDP in women with SLE. This lack of effect may reflect the low event rate in a well-controlled cohort. These findings underscore the need for individualized risk assessment and careful monitoring, beyond reliance on LDA alone, in the management of pregnancies with SLE.
- 13 March 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 760-767
Open AccessEfficacy of low-dose aspirin in preventing hypertensive disorders of pregnancy in women with systemic lupus erythematosus: A single-center retrospective cohort study
Objectives: Low-dose aspirin (LDA) is widely recommended to prevent hypertensive disorders of pregnancy (HDP). However, the evidence of its effectiveness in pregnancies with systemic lupus erythematosus (SLE) remains limited. This study evaluated the efficacy of LDA in preventing HDP in women with SLE. Methods: We conducted a retrospective cohort study of 124 pregnancies with SLE managed at our hospital. Pregnancy outcomes were compared between women treated with LDA and those not treated, using propensity score and inverse probability weighting analyses to adjust for confounders. Results: LDA was used in 65 pregnancies and not used in 59. HDP occurred in 7/65 (10.8%) and 8/59 (13.6%), respectively. After adjusting for potential confounders, including antiphospholipid antibodies, lupus nephritis, chronic hypertension, chronic kidney disease, history of HDP, and hydroxychloroquine use, the risk ratio for HDP with LDA was 0.76 (95% confidence interval: 0.25–2.33; P = .64). Sensitivity analysis was consistent. Conclusions: LDA did not significantly reduce the incidence of HDP in women with SLE. This lack of effect may reflect the low event rate in a well-controlled cohort. These findings underscore the need for individualized risk assessment and careful monitoring, beyond reliance on LDA alone, in the management of pregnancies with SLE.
- 6 March 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 747-752
A case series of rheumatoid arthritis patients exposed to an etanercept biosimilar during pregnancy: Evidence from an increasingly accepted treatment option
Objective: To assess pregnancy and neonatal outcomes in women with rheumatoid arthritis treated with an etanercept biosimilar, and to provide real-world safety evidence. Methods: This retrospective, single-centre study included 11 pregnant women with rheumatoid arthritis who received an etanercept biosimilar at the National Center for Child Health and Development (Tokyo) between October 2018 and March 2022. The clinical characteristics, disease activity, medications, delivery outcomes, and neonatal health were reviewed. Results: All 11 pregnancies were live births. The median maternal age was 34 years, the gestational age at delivery was 39.7 weeks, and the birth weight was 2929 g. One preterm birth (9.1%) and two caesarean deliveries (18.2%) occurred. No cases of low birth weight or neonatal intensive care unit admission were reported. One case of patent foramen ovale was noted. All neonates had 5-minute Apgar scores of ≥9. The etanercept biosimilar was discontinued before delivery in four cases to allow for infant vaccination. Conclusion: Use of the etanercept biosimilar during pregnancy was associated with favourable outcomes, supporting its safety and utility in managing rheumatoid arthritis during pregnancy.
- 6 March 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 747-752
A case series of rheumatoid arthritis patients exposed to an etanercept biosimilar during pregnancy: Evidence from an increasingly accepted treatment option
Objective: To assess pregnancy and neonatal outcomes in women with rheumatoid arthritis treated with an etanercept biosimilar, and to provide real-world safety evidence. Methods: This retrospective, single-centre study included 11 pregnant women with rheumatoid arthritis who received an etanercept biosimilar at the National Center for Child Health and Development (Tokyo) between October 2018 and March 2022. The clinical characteristics, disease activity, medications, delivery outcomes, and neonatal health were reviewed. Results: All 11 pregnancies were live births. The median maternal age was 34 years, the gestational age at delivery was 39.7 weeks, and the birth weight was 2929 g. One preterm birth (9.1%) and two caesarean deliveries (18.2%) occurred. No cases of low birth weight or neonatal intensive care unit admission were reported. One case of patent foramen ovale was noted. All neonates had 5-minute Apgar scores of ≥9. The etanercept biosimilar was discontinued before delivery in four cases to allow for infant vaccination. Conclusion: Use of the etanercept biosimilar during pregnancy was associated with favourable outcomes, supporting its safety and utility in managing rheumatoid arthritis during pregnancy.
- 8 October 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (2) , 181-189
Systematic review of the treatment of rheumatoid arthritis patients of reproductive age: informing the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication
Objectives: To inform the 2024 updates of the Japanese College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis of the safety of maternal and paternal exposure to disease-modifying antirheumatic drugs (DMARDs). Methods: We searched the databases of PubMed, the Cochrane Library, and the Japana Centra Revuo Medicina for articles published between 2019 and 2022 and combined them with our previous systematic review. Two independent reviewers screened articles, evaluated core outcomes, and performed meta-analyses for each clinical question. Results: The relative effects (odds ratio (OR) [95% confidence interval (95% CI)]) of tumour necrosis factor inhibitor (TNFi) exposure on the infants of pregnant women with rheumatoid arthritis were as follows: major birth defects, 1.51 [0.89, 2.58]; and serious neonatal infections, 1.20 [0.84, 1.71]. The relative effects (OR [95% CI]) of paternal antirheumatic drugs exposure on major birth defect in infants were 1.30 [0.28, 6.14] for TNFi and 0.94 [0.38, 2.33] for methotrexate. Conclusions: This systematic review provided the latest evidence on effects of maternal and paternal exposure to DMARDs on their infants for the 2024 update of the clinical practice guidelines.
- 8 October 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (2) , 181-189
Systematic review of the treatment of rheumatoid arthritis patients of reproductive age: informing the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication
Objectives: To inform the 2024 updates of the Japanese College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis of the safety of maternal and paternal exposure to disease-modifying antirheumatic drugs (DMARDs). Methods: We searched the databases of PubMed, the Cochrane Library, and the Japana Centra Revuo Medicina for articles published between 2019 and 2022 and combined them with our previous systematic review. Two independent reviewers screened articles, evaluated core outcomes, and performed meta-analyses for each clinical question. Results: The relative effects (odds ratio (OR) [95% confidence interval (95% CI)]) of tumour necrosis factor inhibitor (TNFi) exposure on the infants of pregnant women with rheumatoid arthritis were as follows: major birth defects, 1.51 [0.89, 2.58]; and serious neonatal infections, 1.20 [0.84, 1.71]. The relative effects (OR [95% CI]) of paternal antirheumatic drugs exposure on major birth defect in infants were 1.30 [0.28, 6.14] for TNFi and 0.94 [0.38, 2.33] for methotrexate. Conclusions: This systematic review provided the latest evidence on effects of maternal and paternal exposure to DMARDs on their infants for the 2024 update of the clinical practice guidelines.
- 7 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy
The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.
- 7 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy
The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.
- 6 May 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (5) , e16303
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report
Hemophilia B is an X‐linked inherited bleeding disorder characterized by decreased coagulation factor IX levels. Female hemophilia carriers can experience bleeding similar to male ones; however, they rarely experience severe bleeding during pregnancy. A 37‐year‐old hemophilia B carrier experienced severe bleeding after a miscarriage. The bleeding was initially controlled with transfusion and uterine artery embolization. However, after several days, the patient exhibited massive bleeding again, which was controlled with coagulation factor IX replacement. In her subsequent pregnancy, the patient presented with subchorionic hematoma and intermittent noncoagulable vaginal bleeding during the first trimester. Coagulation factor IX replacement was administered regularly to maintain coagulation activity to almost 50%. This then resulted in a successful live birth. In addition to conventional treatment for obstetric bleeding, regular coagulation factor IX replacement based on coagulation activity is beneficial during pregnancy in female hemophilia B carriers with recurrent hemorrhagic episodes.
- 6 May 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (5) , e16303
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report
Hemophilia B is an X‐linked inherited bleeding disorder characterized by decreased coagulation factor IX levels. Female hemophilia carriers can experience bleeding similar to male ones; however, they rarely experience severe bleeding during pregnancy. A 37‐year‐old hemophilia B carrier experienced severe bleeding after a miscarriage. The bleeding was initially controlled with transfusion and uterine artery embolization. However, after several days, the patient exhibited massive bleeding again, which was controlled with coagulation factor IX replacement. In her subsequent pregnancy, the patient presented with subchorionic hematoma and intermittent noncoagulable vaginal bleeding during the first trimester. Coagulation factor IX replacement was administered regularly to maintain coagulation activity to almost 50%. This then resulted in a successful live birth. In addition to conventional treatment for obstetric bleeding, regular coagulation factor IX replacement based on coagulation activity is beneficial during pregnancy in female hemophilia B carriers with recurrent hemorrhagic episodes.
- Top Cited Papers
- 17 January 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (3) , 387-401
2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication
Objectives: The aim of this study is to update the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis (CPG for RA). Methods: The recommendations were developed based on the evidence published until the end of June 2022 using the Grading of Recommendations Assessment, Development, and Evaluation. The steering committee, CPG panel, systematic review (SR) group, and SR support team were organised. Results: The treatment goal and drug treatment algorithm required no modifications; however, the footnotes of the drug treatment algorithm were modified. SR of 21 new or updated recommendations for subcutaneous methotrexate (n = 1), biological disease-modifying antirheumatic drugs (n = 1), rituximab (n = 5), Janus kinase inhibitors (n = 6), biosimilars (n = 2), older patients (n = 4), and pregnancy and lactation (n = 2) was conducted. The recommendations for comorbidities and surgery and rehabilitation remained unchanged from the 2020 CPG for RA. Conclusions: The 2024 CPG for RA, which provide recommendations that reflect the current healthcare environment for rheumatoid arthritis in Japan, can be used effectively as a tool for shared decision-making between rheumatologists and patients in the treatment of RA.
- 17 January 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (3) , 387-401
Top Cited Papers2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication
Objectives: The aim of this study is to update the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis (CPG for RA). Methods: The recommendations were developed based on the evidence published until the end of June 2022 using the Grading of Recommendations Assessment, Development, and Evaluation. The steering committee, CPG panel, systematic review (SR) group, and SR support team were organised. Results: The treatment goal and drug treatment algorithm required no modifications; however, the footnotes of the drug treatment algorithm were modified. SR of 21 new or updated recommendations for subcutaneous methotrexate (n = 1), biological disease-modifying antirheumatic drugs (n = 1), rituximab (n = 5), Janus kinase inhibitors (n = 6), biosimilars (n = 2), older patients (n = 4), and pregnancy and lactation (n = 2) was conducted. The recommendations for comorbidities and surgery and rehabilitation remained unchanged from the 2020 CPG for RA. Conclusions: The 2024 CPG for RA, which provide recommendations that reflect the current healthcare environment for rheumatoid arthritis in Japan, can be used effectively as a tool for shared decision-making between rheumatologists and patients in the treatment of RA.